Investors speak out over executive pay at makers of life-saving treatment NHS struggles to afford
The chief executive of a company making a potentially life-saving cystic fibrosis drug that the NHS says is unaffordable was paid $18.8m (£14.4m) in cash and shares last year, the Guardian can reveal.
A circular to shareholders ahead of the company’s upcoming annual meeting showed that Jeff Leiden’s deal was 81 times more than the average Vertex employee was paid and an increase on last year’s $17.2m deal. Separate stock market announcements show that he has also sold more than $70m of company stock over the past two years, some or all of it handed to him as part of his pay deals.
This post was syndicated from Health | The Guardian. Click here to read the full text on the original website.